Medication 8: Larotrectinib (Vitrakvi) – Fighting the NTRK Fusion Gene
Larotrectinib, marketed under the brand name Vitrakvi, takes thyroid cancer treatment into a new dimension by addressing cancers with a specific genetic characteristic called the NTRK gene fusion. This unique genetic feature can occur in various cancers, including certain types of thyroid cancer.
The core functionality of Larotrectinib lies in its ability to target this specific NTRK gene fusion, acting on the cells carrying this biomarker. Its action disrupts the signals that the fused gene sends to stimulate cell proliferation, thereby controlling the spread of the disease.
The capability to target a genetic fusion such as NTRK is a breakthrough in cancer therapeutics. The NTRK fusion, though not common, drives the growth of certain cancers. Hence, for patients with this specific genetic feature, Larotrectinib can be a highly effective line of defense.
Like any medication, Larotrectinib may bring along potential side effects. These can include fatigue, nausea, cough, and constipation. While these effects can be managed effectively with medical supervision, it’s vital for patients to stay in close touch with their healthcare providers.
In summary, Larotrectinib stands as a testament to the advancements in personalized cancer therapy. Its ability to target a specific gene fusion and its significant efficacy in combating cancers harboring this genetic feature make it a crucial tool in treating thyroid cancer. (8)
